Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY2022 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, May 13, 2022
Slide 1: Investor Presentation Q4FY22
Investor Presentation Q4FY22 May 13, 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of FY22
Key Highlights of FY22 • Revenue from Operations grew by 20.0% YoY during FY22, with EBITDA margin at 19.3% and Net Profit growth of 3.8% YoY • India Business: Company’s secondary sales in FY22 registered growth of 27.6% YoY compared to IPM growth of 18.2% YoY (Source: IQVIA data) • Strong growth in
Slide 4: Key Financial Highlights – Q4FY22 (Consolidated)
Key Financial Highlights – Q4FY22 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 17,187 14,732 24,839 21,922 Q4FY21 Q4FY22 International sales 7,411 6,907 Q4FY21 Q4FY22 Q4FY21 Q4FY22
Slide 5: Key Financial Highlights – Q4FY22 (Consolidated)
Key Financial Highlights – Q4FY22 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 14,525 3,372 12,492 2,911 57.0% 58.5% 13.3% 13.6% Q4FY21 Q4FY22 Q4FY21 Q4FY22 PBT (before Minority Interest) PAT (after Minority Interest) Q4FY22 PAT was impacted by 2,400 exce
Slide 6: Key Financial Highlights – FY22 (Consolidated)
Key Financial Highlights – FY22 (Consolidated) All figures in ₹ mn Particulars (₹ mn) FY22 FY21 YoY growth Revenue from Operations 106,342 88,650 20.0% Gross Profit 64,539 53,665 20.3% Gross Profit margin 60.7% 60.5% EBITDA 20,529 19,424 5.7% EBITDA margin 19.3% 21.9% PBT 18,443 18,421 0.1% PBT marg
Slide 7: India Business
India Business India Business: Q4FY22 Sales of ₹ 17,187 million (16.7% YoY growth) • India sales contributed 69.9% to total sales in Q4FY22 • In Q4FY22, the Company’s secondary sales grew by 15.3% YoY compared to IPM growth of 9.6% YoY (Source: IQVIA data) • Growth was mainly led by acute therapies
Slide 8: Secondary Sales Performance
Secondary Sales Performance Healthy growth across all the major therapeutic segments in FY22 +2 Acute Therapies Market rank 1 3 3 2 33.8% 35.0% 30.1% 22.2% 22.0% 21.6% 17.4% 16.4% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem sales growth YoY1,2 Indian pharm
Slide 9: US Business
US Business US Business: Q4FY22 Sales of ₹ 5,419 million (YoY decline of 0.3%) • US sales contributed 22.0% to total sales in Q4FY22 • Growth during the quarter and year was impacted by significant pricing pressure in the US generic market • During the quarter Q4FY22, the Company filed 6 ANDAs with
Slide 10: US Business – Update on US FDA inspections
US Business Update on US FDA inspections Manufacturing Capability Last inspection Status post last inspection facility Bioequivalence Taloja (India) April 2022 Successfully closed inspection without any observations Centre St. Louis (US) Formulations June 2021 Inspection is closed. EIR# received in
Slide 11: Other International Business
Other International Business Other International Business: Q4FY22 Sales of ₹ 1,991 million (35.3% YoY growth) • Other International Market sales contributed 8.1% to total sales in Q4FY22 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key markets lik
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on March 31, 2022 Non-Institution, 23.32% Promoter & Promoter Group, 57.13% Institution, 19.55% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodi
Slide 13: Thank You
Thank You For further information or queries, please contact Gagan Borana Investor Relations Tel: +91 22 3982 9960 E-mail: [email protected]